{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:48:01Z","timestamp":1789804081297,"version":"4.0.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T00:00:00Z","timestamp":1449619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/leu.2015.334","type":"journal-article","created":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T02:40:43Z","timestamp":1449628843000},"page":"873-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["FOXM1 is a therapeutic target for high-risk multiple myeloma"],"prefix":"10.1038","volume":"30","author":[{"given":"C","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sompallae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V S","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Janz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"BFleu2015334_CR1","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020\u20132028.","journal-title":"Blood"},{"key":"BFleu2015334_CR2","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"Jr Shaughnessy JD","year":"2007","unstructured":"Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276\u20132284.","journal-title":"Blood"},{"key":"BFleu2015334_CR3","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012; 26: 2406\u20132413.","journal-title":"Leukemia"},{"key":"BFleu2015334_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3109\/10428194.2014.911863","volume":"56","author":"P Wu","year":"2015","unstructured":"Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R et al. A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. Leuk Lymphoma 2015; 56: 594\u2013601.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015334_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ajh.22237","volume":"87","author":"SV Rajkumar","year":"2012","unstructured":"Rajkumar SV . Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 78\u201388.","journal-title":"Am J Hematol"},{"key":"BFleu2015334_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbagrm.2011.09.004","volume":"1819","author":"CY Koo","year":"2012","unstructured":"Koo CY, Muir KW, Lam EW . FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819: 28\u201337.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2015334_CR7","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-12-0953","volume":"72","author":"A Gong","year":"2012","unstructured":"Gong A, Huang S . FoxM1 and Wnt\/beta-catenin signaling in glioma stem cells. Cancer Res 2012; 72: 5658\u20135662.","journal-title":"Cancer Res"},{"key":"BFleu2015334_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","volume":"68","author":"W Matsui","year":"2008","unstructured":"Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190\u2013197.","journal-title":"Cancer Res"},{"key":"BFleu2015334_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12563","volume":"163","author":"R Hajek","year":"2013","unstructured":"Hajek R, Okubote SA, Svachova H . Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 2013; 163: 551\u2013564.","journal-title":"Br J Haematol"},{"key":"BFleu2015334_CR10","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1158\/0008-5472.CAN-04-4059","volume":"65","author":"DR Wonsey","year":"2005","unstructured":"Wonsey DR, Follettie MT . Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005; 65: 5181\u20135189.","journal-title":"Cancer Res"},{"key":"BFleu2015334_CR11","first-page":"92","volume":"1775","author":"J Laoukili","year":"2007","unstructured":"Laoukili J, Stahl M, Medema RH . FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007; 1775: 92\u2013102.","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"BFleu2015334_CR12","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1517\/14712598.2013.814637","volume":"13","author":"P Neri","year":"2013","unstructured":"Neri P, Bahlis NJ . Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opin Biol Ther 2013; 13 (Suppl 1): S69\u2013S82.","journal-title":"Expert Opin Biol Ther"},{"key":"BFleu2015334_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3324\/haematol.2011.053421","volume":"97","author":"S Uddin","year":"2012","unstructured":"Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P et al. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica 2012; 97: 1092\u20131100.","journal-title":"Haematologica"},{"key":"BFleu2015334_CR14","doi-asserted-by":"publisher","first-page":"e76889","DOI":"10.1371\/journal.pone.0076889","volume":"8","author":"VS Tompkins","year":"2013","unstructured":"Tompkins VS, Han SS, Olivier A, Syrbu S, Bair T, Button A et al. Identification of candidate B-lymphoma genes by cross-species gene expression profiling. PLoS One 2013; 8: e76889.","journal-title":"PLoS One"},{"key":"BFleu2015334_CR15","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-12-3859","volume":"73","author":"X Kong","year":"2013","unstructured":"Kong X, Li L, Li Z, Le X, Huang C, Jia Z et al. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Cancer Res 2013; 73: 3987\u20133996.","journal-title":"Cancer Res"},{"key":"BFleu2015334_CR16","doi-asserted-by":"publisher","first-page":"22527","DOI":"10.1074\/jbc.M113.455089","volume":"288","author":"Y Cai","year":"2013","unstructured":"Cai Y, Balli D, Ustiyan V, Fulford L, Hiller A, Misetic V et al. Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. J Biol Chem 2013; 288: 22527\u201322541.","journal-title":"J Biol Chem"},{"key":"BFleu2015334_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1535-7163.MCT-12-0903","volume":"12","author":"Z Wang","year":"2013","unstructured":"Wang Z, Zheng Y, Park HJ, Li J, Carr JR, Chen YJ et al. Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma. Mol Cancer Ther 2013; 12: 759\u2013767.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2015334_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/leu.2014.341","volume":"29","author":"T Motiwala","year":"2015","unstructured":"Motiwala T, Kutay H, Zanesi N, Frissora FW, Mo X, Muthusamy N et al. PTPROt-mediated regulation of p53\/Foxm1 suppresses leukemic phenotype in a CLL mouse model. Leukemia 2015; 29: 1350\u20131359.","journal-title":"Leukemia"},{"key":"BFleu2015334_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jhep.2015.03.023","volume":"63","author":"D Kopanja","year":"2015","unstructured":"Kopanja D, Pandey A, Kiefer M, Wang Z, Chandan N, Carr JR et al. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features. J Hepatol 2015; 63: 429\u2013436.","journal-title":"J Hepatol"},{"key":"BFleu2015334_CR20","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.bbagrm.2014.09.016","volume":"1839","author":"S Zona","year":"2014","unstructured":"Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW . FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta 2014; 1839: 1316\u20131322.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2015334_CR21","doi-asserted-by":"publisher","first-page":"e34329","DOI":"10.1371\/journal.pone.0034329","volume":"7","author":"MT Teh","year":"2012","unstructured":"Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, Bahta AW et al. FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One 2012; 7: e34329.","journal-title":"PLoS One"},{"key":"BFleu2015334_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1667\/RR13726.1","volume":"182","author":"JC Eckers","year":"2014","unstructured":"Eckers JC, Kalen AL, Sarsour EH, Tompkins VS, Janz S, Son JM et al. Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells. Radiat Res 2014; 182: 420\u2013429.","journal-title":"Radiat Res"},{"key":"BFleu2015334_CR23","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/onc.2015.208","volume":"35","author":"U Karunarathna","year":"2016","unstructured":"Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR et al. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene 2016; 35: 1433\u20131444.","journal-title":"Oncogene"},{"key":"BFleu2015334_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/ni.3204","volume":"16","author":"Y Hou","year":"2015","unstructured":"Hou Y, Li W, Sheng Y, Li L, Huang Y, Zhang Z et al. The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells. Nat Immunol 2015; 16: 810\u2013818.","journal-title":"Nat Immunol"},{"key":"BFleu2015334_CR25","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/0008-5472.CAN-14-2800","volume":"75","author":"AH Gong","year":"2015","unstructured":"Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD et al. FoxM1 drives a feed-forward STAT3-activation signaling loop that promotes the self-renewal and tumorigenicity of glioblastoma stem-like cells. Cancer Res 2015; 75: 2337\u20132348.","journal-title":"Cancer Res"},{"key":"BFleu2015334_CR26","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.18632\/oncotarget.2957","volume":"6","author":"WT Chiu","year":"2015","unstructured":"Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC et al. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 2015; 6: 2349\u20132365.","journal-title":"Oncotarget"},{"key":"BFleu2015334_CR27","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1038\/ncomms6165","volume":"5","author":"MV Gormally","year":"2014","unstructured":"Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinkovic D et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun 2014; 5: 5165.","journal-title":"Nat Commun"},{"key":"BFleu2015334_CR28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.bcp.2012.10.013","volume":"85","author":"M Halasi","year":"2013","unstructured":"Halasi M, Gartel AL . Targeting FOXM1 in cancer. Biochem Pharmacol 2013; 85: 644\u2013652.","journal-title":"Biochem Pharmacol"},{"key":"BFleu2015334_CR29","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood.V67.6.1542.1542","volume":"67","author":"AF Gazdar","year":"1986","unstructured":"Gazdar AF, Oie HK, Kirsch IR, Hollis GF . Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 1986; 67: 1542\u20131549.","journal-title":"Blood"},{"key":"BFleu2015334_CR30","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","volume":"83","author":"XG Zhang","year":"1994","unstructured":"Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654\u20133663.","journal-title":"Blood"},{"key":"BFleu2015334_CR31","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1182\/blood.V93.9.3044","volume":"93","author":"R Feinman","year":"1999","unstructured":"Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS . Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044\u20133052.","journal-title":"Blood"},{"key":"BFleu2015334_CR32","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","volume":"66","author":"LB Baughn","year":"2006","unstructured":"Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6. Cancer Res 2006; 66: 7661\u20137667.","journal-title":"Cancer Res"},{"key":"BFleu2015334_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/gcc.20404","volume":"46","author":"L Lombardi","year":"2007","unstructured":"Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46: 226\u2013238.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2015334_CR34","unstructured":"Yellapantula V, Divya T, Dinu V, Scotch M . Informatics approaches for integrative analysis of disparate high-throughput genomic datasets in cander. Arizona State University (ASU) Electronic Dissertations and Theses Digital Repository, 2014."},{"key":"BFleu2015334_CR35","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1182\/blood-2013-02-482919","volume":"122","author":"Y Yang","year":"2013","unstructured":"Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H et al. RARalpha2 expression confers myeloma stem cell features. Blood 2013; 122: 1437\u20131447.","journal-title":"Blood"},{"key":"BFleu2015334_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","volume":"5","author":"EM Hurt","year":"2004","unstructured":"Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191\u2013199.","journal-title":"Cancer Cell"},{"key":"BFleu2015334_CR37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/sj.leu.2404602","volume":"21","author":"M Romagnoli","year":"2007","unstructured":"Romagnoli M, Trichet V, David C, Clement M, Moreau P, Bataille R et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007; 21: 1070\u20131078.","journal-title":"Leukemia"},{"key":"BFleu2015334_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","volume":"75","author":"Y Yang","year":"2015","unstructured":"Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E et al. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res 2015; 75: 594\u2013604.","journal-title":"Cancer Res"},{"key":"BFleu2015334_CR39","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM . A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418\u20135422.","journal-title":"Blood"},{"key":"BFleu2015334_CR40","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","volume":"116","author":"F van Rhee","year":"2010","unstructured":"van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116: 1220\u20131227.","journal-title":"Blood"},{"key":"BFleu2015334_CR41","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood-2012-03-415588","volume":"120","author":"A Seckinger","year":"2012","unstructured":"Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 2012; 120: 1087\u20131094.","journal-title":"Blood"},{"key":"BFleu2015334_CR42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nchem.1114","volume":"3","author":"NS Hegde","year":"2011","unstructured":"Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S . The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 2011; 3: 725\u2013731.","journal-title":"Nat Chem"},{"key":"BFleu2015334_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13059-015-0696-z","volume":"16","author":"DA Sanders","year":"2015","unstructured":"Sanders DA, Gormally MV, Marsico G, Beraldi D, Tannahill D, Balasubramanian S . FOXM1 binds directly to non-consensus sequences in the human genome. Genome Biol 2015; 16: 130.","journal-title":"Genome Biol"},{"key":"BFleu2015334_CR44","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","volume":"20","author":"L Anders","year":"2011","unstructured":"Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM et al. A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20: 620\u2013634.","journal-title":"Cancer Cell"},{"key":"BFleu2015334_CR45","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3324\/haematol.2010.022210","volume":"95","author":"H Chang","year":"2010","unstructured":"Chang H, Jiang N, Jiang H, Saha MN, Qi C, Xu W et al. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. Haematologica 2010; 95: 1542\u20131547.","journal-title":"Haematologica"},{"key":"BFleu2015334_CR46","doi-asserted-by":"publisher","first-page":"e42141","DOI":"10.1371\/journal.pone.0042141","volume":"7","author":"HD Nischalke","year":"2012","unstructured":"Nischalke HD, Schmitz V, Luda C, Aldenhoff K, Berger C, Feldmann G et al. Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures. PLoS One 2012; 7: e42141.","journal-title":"PLoS One"},{"key":"BFleu2015334_CR47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/gut.2008.152652","volume":"58","author":"DF Calvisi","year":"2009","unstructured":"Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M et al. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2009; 58: 679\u2013687.","journal-title":"Gut"},{"key":"BFleu2015334_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","volume":"23","author":"W Zhou","year":"2013","unstructured":"Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013; 23: 48\u201362.","journal-title":"Cancer Cell"},{"key":"BFleu2015334_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3892\/or.2013.2910","volume":"31","author":"X Liu","year":"2014","unstructured":"Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F . Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep 2014; 31: 745\u2013754.","journal-title":"Oncol Rep"},{"key":"BFleu2015334_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2741\/4212","volume":"19","author":"M Marina","year":"2014","unstructured":"Marina M, Saavedra HI . Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed) 2014; 19: 352\u2013365.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"BFleu2015334_CR51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.105","volume":"1","author":"L Shi","year":"2010","unstructured":"Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C et al. Over-expression of CKS1B activates both MEK\/ERK and JAK\/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010; 1: 22\u201333.","journal-title":"Oncotarget"},{"key":"BFleu2015334_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/blood-2013-08-524025","volume":"123","author":"T Tanno","year":"2013","unstructured":"Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G et al. Growth Differentiating Factor 15 enhances the tumor initiating and self-renewal potential of multiple myeloma cells. Blood 2013; 123: 725\u2013733.","journal-title":"Blood"},{"key":"BFleu2015334_CR53","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1038\/ncomms8539","volume":"6","author":"E Ziv","year":"2015","unstructured":"Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun 2015; 6: 7539.","journal-title":"Nat Commun"},{"key":"BFleu2015334_CR54","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1038\/bcj.2013.53","volume":"3","author":"Y Hu","year":"2013","unstructured":"Hu Y, Zheng M, Gali R, Tian Z, Topal Gorgun G, Munshi NC et al. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB\/c mice. Blood Cancer J 2013; 3: e156.","journal-title":"Blood Cancer J"},{"key":"BFleu2015334_CR55","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1172\/JCI69094","volume":"124","author":"T Dechow","year":"2014","unstructured":"Dechow T, Steidle S, Gotze KS, Rudelius M, Behnke K, Pechloff K et al. GP130 activation induces myeloma and collaborates with MYC. J Clin Invest 2014; 124: 5263\u20135274.","journal-title":"J Clin Invest"},{"key":"BFleu2015334_CR56","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/leu.2015.197","volume":"30","author":"VS Tompkins","year":"2016","unstructured":"Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM et al. Adoptive B-cell transfer mouse model of human myeloma. Leukemia 2016; 30: 962\u2013966.","journal-title":"Leukemia"},{"key":"BFleu2015334_CR57","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","volume":"120","author":"M Chesi","year":"2012","unstructured":"Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012; 120: 376\u2013385.","journal-title":"Blood"},{"key":"BFleu2015334_CR58","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","volume":"17","author":"EC Lee","year":"2011","unstructured":"Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011; 17: 7313\u20137323.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015334_CR59","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1038\/bcj.2013.61","volume":"3","author":"K Duncan","year":"2013","unstructured":"Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F et al. (18)F-FDG-PET\/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J 2013; 3: e165.","journal-title":"Blood Cancer J"},{"key":"BFleu2015334_CR60","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.3109\/10428194.2015.1030641","volume":"56","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA et al. Phase 1\/2 study of cyclin-dependent kinase (CDK)4\/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. Leuk Lymphoma 2015; 56: 3320\u20133328.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015334_CR61","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1039\/C4OB02238F","volume":"13","author":"P Innocenti","year":"2015","unstructured":"Innocenti P, Woodward H, O'Fee L, Hoelder S . Expanding the scope of fused pyrimidines as kinase inhibitor scaffolds: synthesis and modification of pyrido[3,4-d]pyrimidines. Org Biomol Chem 2015; 13: 893\u2013904.","journal-title":"Org Biomol Chem"},{"key":"BFleu2015334_CR62","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/onc.2014.67","volume":"34","author":"CM Hu","year":"2015","unstructured":"Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B et al. Novel small molecules disrupting Hec1\/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene 2015; 34: 1220\u20131230.","journal-title":"Oncogene"},{"key":"BFleu2015334_CR63","doi-asserted-by":"publisher","first-page":"e6593","DOI":"10.1371\/journal.pone.0006593","volume":"4","author":"UG Bhat","year":"2009","unstructured":"Bhat UG, Halasi M, Gartel AL . FoxM1 is a general target for proteasome inhibitors. PLoS One 2009; 4: e6593.","journal-title":"PLoS One"},{"key":"BFleu2015334_CR64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 2015; 125: 90\u2013101.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015334","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:13:03Z","timestamp":1648728783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFleu2015334"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.334","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]},"assertion":[{"value":"28 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}